Middle East and Africa In Vitro Diagnostics Market Outlook to 2017 – Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

2012-01-16
Published : Jan-2012

GlobalData’s new report, “Middle East and Africa In Vitro Diagnostics Market Outlook to 2017 – Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the  Middle East and Africa In Vitro Diagnostics  market – Israel, Saudi Arabia and South Africa. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

Middle East and Africa In Vitro Diagnostics Market Outlook to 2017

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

  • Countries covered include Israel, Saudi Arabia and South Africa.
  • Market size and company share data for  In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
  • Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2003 to 2010, forecast forward for 7 years to 2017.
  • 2010 company shares and distribution shares data for each of the market categories and countries.
  • Global corporate-level profiles of key companies operating within the Middle East and Africa In Vitro Diagnostics market..
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Becton, Dickinson and Company and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Middle East and Africa In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 10

2 Introduction 12
2.1 What is This Report About? 12

3 In Vitro Diagnostics in Middle East and Africa 13
3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017 13
3.2 In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, 2003-2017 14
3.3 In Vitro Diagnostics, Middle East and Africa, Company share (2009-2010) 22

4 In Vitro Diagnostics In Israel 24
4.1 In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, 2003-2017 24
4.2 In Vitro Diagnostics, Israel, Distribution Share (2009-2010) 30
4.2.1 Clinical Chemistry, Israel, Distribution Share (2009-2010) 30
4.2.2 Genetic Testing, Israel, Distribution Share (2009-2010) 30
4.2.3 Haematology, Israel, Distribution Share (2009-2010) 31
4.2.4 Histology And Cytology, Israel, Distribution Share (2009-2010) 31
4.2.5 Immuno Chemistry, Israel, Distribution Share (2009-2010) 32
4.2.6 Infectious Immunology, Israel, Distribution Share (2009-2010) 32
4.2.7 Microbiology Culture, Israel, Distribution Share (2009-2010) 33
4.3 In Vitro Diagnostics, Israel, Company share (2009-2010) 34
4.3.1 In Vitro Diagnostics, Israel, Company share (2009-2010) 34
4.3.2 Clinical Chemistry, Israel, Company share (2009-2010) 36
4.3.3 Genetic Testing, Israel, Company share (2009-2010) 38
4.3.4 Haematology, Israel, Company share (2009-2010) 40
4.3.5 Histology And Cytology, Israel, Company share (2009-2010) 42
4.3.6 Immuno Chemistry, Israel, Company share (2009-2010) 44
4.3.7 Infectious Immunology, Israel, Company share (2009-2010) 46
4.3.8 Microbiology Culture, Israel, Company share (2009-2010) 48

5 In Vitro Diagnostics In South Africa 50
5.1 In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 50
5.2 In Vitro Diagnostics, South Africa, Distribution Share (2009-2010) 56
5.2.1 Clinical Chemistry, South Africa, Distribution Share (2009-2010) 56
5.2.2 Genetic Testing, South Africa, Distribution Share (2009-2010) 56
5.2.3 Haematology, South Africa, Distribution Share (2009-2010) 57
5.2.4 Histology And Cytology, South Africa, Distribution Share (2009-2010) 57
5.2.5 Immuno Chemistry, South Africa, Distribution Share (2009-2010) 58
5.2.6 Infectious Immunology, South Africa, Distribution Share (2009-2010) 58
5.2.7 Microbiology Culture, South Africa, Distribution Share (2009-2010) 59
5.3 In Vitro Diagnostics, South Africa, Company share (2009-2010) 59
5.3.1 In Vitro Diagnostics, South Africa, Company share (2009-2010) 59
5.3.2 Clinical Chemistry, South Africa, Company share (2009-2010) 62
5.3.3 Genetic Testing, South Africa, Company share (2009-2010) 64
5.3.4 Haematology, South Africa, Company share (2009-2010) 66
5.3.5 Histology And Cytology, South Africa, Company share (2009-2010) 68
5.3.6 Immuno Chemistry, South Africa, Company share (2009-2010) 70
5.3.7 Infectious Immunology, South Africa, Company share (2009-2010) 72
5.3.8 Microbiology Culture, South Africa, Company share (2009-2010) 74

6 In Vitro Diagnostics In Saudi Arabia 76
6.1 In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, 2003-2017 76
6.2 In Vitro Diagnostics, Saudi Arabia, Distribution Share (2009-2010) 82
6.2.1 Clinical Chemistry, Saudi Arabia, Distribution Share (2009-2010) 82
6.2.2 Genetic Testing, Saudi Arabia, Distribution Share (2009-2010) 82
6.2.3 Haematology, Saudi Arabia, Distribution Share (2009-2010) 83
6.2.4 Histology And Cytology, Saudi Arabia, Distribution Share (2009-2010) 83
6.2.5 Immuno Chemistry, Saudi Arabia, Distribution Share (2009-2010) 84
6.2.6 Infectious Immunology, Saudi Arabia, Distribution Share (2009-2010) 84
6.2.7 Microbiology Culture, Saudi Arabia, Distribution Share (2009-2010) 85
6.3 In Vitro Diagnostics, Saudi Arabia, Company share (2009-2010) 86
6.3.1 In Vitro Diagnostics, Saudi Arabia, Company share (2009-2010) 86
6.3.2 Clinical Chemistry, Saudi Arabia, Company share (2009-2010) 88
6.3.3 Genetic Testing, Saudi Arabia, Company share (2009-2010) 90
6.3.4 Haematology, Saudi Arabia, Company share (2009-2010) 92
6.3.5 Histology And Cytology, Saudi Arabia, Company share (2009-2010) 94
6.3.6 Immuno Chemistry, Saudi Arabia, Company share (2009-2010) 96
6.3.7 Infectious Immunology, Saudi Arabia, Company share (2009-2010) 98
6.3.8 Microbiology Culture, Saudi Arabia, Company share (2009-2010) 100

7 Overview of Key Companies in Middle East and Africa In Vitro Diagnostics Market 102
7.1 F. Hoffmann-La Roche Ltd. 102
7.1.1 Company Overview 102
7.1.2 Share in the Middle East and Africa In Vitro Diagnostics Market 102
7.2 Siemens Healthcare 103
7.2.1 Company Overview 103
7.2.2 Share in the Middle East and Africa In Vitro Diagnostics Market 103
7.3 Abbott Laboratories 104
7.3.1 Company Overview 104
7.3.2 Share in the Middle East and Africa In Vitro Diagnostics Market 104
7.4 Beckman Coulter, Inc. 105
7.4.1 Company Overview 105
7.4.2 Share in the Middle East and Africa In Vitro Diagnostics Market 105
7.5 bioMerieux S.A. 106
7.5.1 Company Overview 106
7.5.2 Share in the Middle East and Africa In Vitro Diagnostics Market 106
7.6 Becton, Dickinson and Company 107
7.6.1 Company Overview 107
7.6.2 Share in the Middle East and Africa In Vitro Diagnostics Market 107
7.7 Ortho-Clinical Diagnostics Inc. 108
7.7.1 Company Overview 108
7.8 Bio-Rad Laboratories, Inc. 108
7.8.1 Company Overview 108
7.9 Mindray Medical International Limited 108
7.9.1 Company Overview 108
7.10 DiaSorin S.p.A 109
7.10.1 Company Overview 109
7.11 Sysmex Corporation 109
7.11.1 Company Overview 109
7.12 HORIBA, Ltd. 109
7.12.1 Company Overview 109
7.13 Qiagen N.V. 110
7.13.1 Company Overview 110
7.14 Thermo Fisher Scientific Inc. 110
7.14.1 Company Overview 110
7.15 Grifols, S.A. 111
7.15.1 Company Overview 111
7.16 Alere Inc. 111
7.16.1 Company Overview 111
7.17 Gen-Probe Incorporated 112
7.17.1 Company Overview 112
7.18 Phadia AB 112
7.18.1 Company Overview 112
7.19 DIAGNOSTICA STAGO, Inc. 112
7.19.1 Company Overview 112
7.20 Life Technologies Corporation 113
7.20.1 Company Overview 113
7.21 PerkinElmer, Inc. 113
7.21.1 Company Overview 113
7.22 Hologic, Inc. 114
7.22.1 Company Overview 114
7.23 Immucor, Inc. 114
7.23.1 Company Overview 114
7.24 Chembio Diagnostic, Inc. 115
7.24.1 Company Overview 115

8 In Vitro Diagnostics Market Pipeline Products 116
8.1 Clinical Chemisty Market Pipeline Products 116
8.2 Immuno Chemistry Market Pipeline Products 119
8.3 Haematology Market Pipeline Products 122
8.4 Infectious Immunology Market Pipeline Products 124
8.5 Microbiology Culture Market Pipeline Products 128
8.6 Histology and Cytology Market Pipeline Products 129
8.7 Genetic Testing Market Pipeline Products 130

9 Financial Deals Landscape 134
9.1 Acquisition 134
9.1.1 Al Borg Laboratory Acquires Majority Stake In Biolab 134
9.1.2 Micromedic Technologies To Acquire Zetiq Technologies 135
9.2 Partnerships 137
9.2.1 Vermillion Enters Into Distribution Agreement With Pronto Diagnostics 137
9.2.2 Procognia Enters Into Co-Development Agreement With Caerus Discovery 138
9.2.3 BioMarCare Technologies Enters Into Co-Development Agreement With Ariadne 139
9.2.4 Signal Genetics Enters Into Distribution Agreement With Pronto Diagnostics 140
9.2.5 Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 141
9.2.6 Rosetta Genomics Enters Into Agreement With Carmel Medical Center 142

10 Recent Developments 143
10.1 Strategy And Business Planning 143
10.1.1 Oct 11, 2011: Rosetta Genomics Restructures To Reduce Operating Expenses And Focus On Commercial Opportunities 143
10.2 Government and Public Interest 143
10.2.1 Sep 19, 2011: PerkinElmer Helps Egypt’s MOHP Build World’s Largest Newborn Screening Laboratory 143
10.2.2 Jul 25, 2011: Roche To Provide HIV/AIDS Tests For Early Infant Diagnosis In South Africa 144
10.2.3 Jan 18, 2011: Mindray Medical To Exhibit At Arab Health 2011 In Dubai 145
10.3 Product News 146
10.3.1 Oct 17, 2011: Signature Mapping Receives Order For TBDx Automated Tuberculosis Diagnostic Systems 146
10.3.2 Sep 16, 2011: FDA Grants Humanitarian Use Designation For Exalenz Bioscience’s BreathID MBT Test For Acute Liver Failure 146
10.3.3 Sep 14, 2011: Signature Mapping TBDx Tuberculosis Diagnostics Solution To Be Deployed In Remote Intensive Case Finding Project 147
10.3.4 Mar 25, 2010: Study Finds Standardized Measure Using SMARTube Technology To Estimate Rate Of Spread Of HIV In High-Risk Populations 147
10.3.5 Mar 23, 2010: ACC Conference Highlights Studies On Assessing Cardiovascular Risk Using Itamar-Medical’s EndoPAT In High And Low Risk Patients 148
10.3.6 Feb 04, 2010: Arrayit Gains Patent Protection From Israel For Its VIP DNA Testing Technology 149
10.3.7 Jan 11, 2010: HairDX Forms Alliance For Distribution Of HairDX Genetic Test In South Africa 149

11 Appendix 150
11.1 Definitions of Markets Covered in the Report 151
11.1.1 In Vitro Diagnostics 151
11.2 Research Methodology 152
11.3 Secondary Research 152
11.4 Primary Research 153
11.5 Models 153
11.6 Forecasts 154
11.7 Expert Panels 154
11.8 GlobalData Consulting 154
11.9 Currency Conversion 155
11.10 Contact Us 155
11.11 Disclaimer 155

List of Tables

Table 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 13
Table 2: In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, 2003-2017 15
Table 3:  In Vitro Diagnostics, Middle East and Africa, Cross-Category Analysis, 2003-2017 17
Table 4: In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 19
Table 5: In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 21
Table 6: In Vitro Diagnostics, Middle East and Africa, Company share by Revenue ($m), USD Actual, 2009-2010 23
Table 7: In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, 2003-2017 25
Table 8: In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, Historic, 2003-2010 27
Table 9: In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 29
Table 10: Clinical Chemistry, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 30
Table 11: Genetic Testing, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 30
Table 12: Haematology, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 31
Table 13: Histology And Cytology, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 31
Table 14: Immuno Chemistry, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 32
Table 15: Infectious Immunology, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 32
Table 16: Microbiology Culture, Israel, Distribution Share by Revenue ($m), USD Actual, 2009-2010 33
Table 17: In Vitro Diagnostics, Israel, Company share by Revenue ($m), USD Actual, 2009-2010 35
Table 18: Clinical Chemistry, Israel, Company share by Revenue ($m), USD Actual 2009-2010 37
Table 19: Genetic Testing, Israel, Company share by Revenue ($m), USD Actual 2009-2010 39
Table 20: Haematology, Israel, Company share by Revenue ($m), USD Actual 2009-2010 41
Table 21: Histology And Cytology, Israel, Company share by Revenue ($m), USD Actual 2009-2010 43
Table 22: Immuno Chemistry, Israel, Company share by Revenue ($m), USD Actual 2009-2010 45
Table 23: Infectious Immunology, Israel, Company share by Revenue ($m), USD Actual 2009-2010 47
Table 24: Microbiology Culture, Israel, Company Share by Revenue ($m), USD Actual 2009-2010 49
Table 25: In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 51
Table 26: In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 53
Table 27: In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 55
Table 28: Clinical Chemistry, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 56
Table 29: Genetic Testing, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 56
Table 30: Haematology, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 57
Table 31: Histology And Cytology, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 57
Table 32: Immuno Chemistry, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 58
Table 33: Infectious Immunology, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 58
Table 34: Microbiology Culture, South Africa, Distribution Share by Revenue ($m), USD Actual, 2009-2010 59
Table 35: In Vitro Diagnostics, South Africa, Company share by Revenue ($m), USD Actual, 2009-2010 61
Table 36: Clinical Chemistry, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 63
Table 37: Genetic Testing, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 65
Table 38: Haematology, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 67
Table 39: Histology And Cytology, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 69
Table 40: Immuno Chemistry, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 71
Table 41: Infectious Immunology, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 73
Table 42: Microbiology Culture, South Africa, Company share by Revenue ($m), USD Actual 2009-2010 75
Table 43: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, 2003-2017 77
Table 44: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, Historic, 2003-2010 79
Table 45: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 81
Table 46: Clinical Chemistry, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 82
Table 47: Genetic Testing, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 82
Table 48: Haematology, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 83
Table 49: Histology And Cytology, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 83
Table 50: Immuno Chemistry, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 84
Table 51: Infectious Immunology, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 84
Table 52: Microbiology Culture, Saudi Arabia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 85
Table 53: In Vitro Diagnostics, Saudi Arabia, Company share by Revenue ($m), USD Actual, 2009-2010 87
Table 54: Clinical Chemistry, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 89
Table 55: Genetic Testing, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 91
Table 56: Haematology, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 93
Table 57: Histology And Cytology, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 95
Table 58: Immuno Chemistry, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 97
Table 59: Infectious Immunology, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 99
Table 60: Microbiology Culture, Saudi Arabia, Company share by Revenue ($m), USD Actual 2009-2010 101
Table 61: Clinical Chemisty Market Pipeline Products 116
Table 62: Immuno Chemistry Market Pipeline Products 119
Table 63: Haematology Market Pipeline Products 122
Table 64: Infectious Immunology Market Pipeline Products 124
Table 65: Microbiology Culture Market Pipeline Products 128
Table 66: Histology and Cytology Market Pipeline Products 129
Table 67: Genetic Testing Market Pipeline Products 130
Table 68: Al Borg Laboratory Acquires Majority Stake In Biolab 134
Table 69: Micromedic Technologies To Acquire Zetiq Technologies 135
Table 70: Vermillion Enters Into Distribution Agreement With Pronto Diagnostics 137
Table 71: Procognia Enters Into Co-Development Agreement With Caerus Discovery 138
Table 72: BioMarCare Technologies Enters Into Co-Development Agreement With Ariadne 139
Table 73: Signal Genetics Enters Into Distribution Agreement With Pronto Diagnostics 140
Table 74: Rosetta Genomics Enters Into Agreement With Tel Hashomer Medical Research, Infrastructure And Services 141
Table 75: Rosetta Genomics Enters Into Agreement With Carmel Medical Center 142
Table 76: USD to Local Currency, Middle East And Africa, Average Exchange Rate 2003-2010 155

List of Figures

Figure 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 13
Figure 2: In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, 2003-2017 14
Figure 3:  In Vitro Diagnostics, Middle East and Africa, Cross-Category Analysis, 2003-2017 16
Figure 4: In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 18
Figure 5: In Vitro Diagnostics, Middle East and Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 20
Figure 6: In Vitro Diagnostics, Middle East and Africa, Company share (%), 2010 22
Figure 7: In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, 2003-2017 24
Figure 8: In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, Historic, 2003-2010 26
Figure 9: In Vitro Diagnostics, Israel, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 28
Figure 10: In Vitro Diagnostics, Israel, Company share (%), 2010 34
Figure 11: Clinical Chemistry, Israel, Company share (%), 2010 36
Figure 12: Genetic Testing, Israel, Company share (%), 2010 38
Figure 13: Haematology, Israel, Company share (%), 2010 40
Figure 14: Histology And Cytology, Israel, Company share (%), 2010 42
Figure 15: Immuno Chemistry, Israel, Company share (%), 2010 44
Figure 16: Infectious Immunology, Israel, Company share (%), 2010 46
Figure 17: Microbiology Culture, Israel, Company Share (%), 2010 48
Figure 18: In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 50
Figure 19: In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 52
Figure 20: In Vitro Diagnostics, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 54
Figure 21: In Vitro Diagnostics, South Africa, Company share (%), 2010 59
Figure 22: Clinical Chemistry, South Africa, Company share (%), 2010 62
Figure 23: Genetic Testing, South Africa, Company share (%), 2010 64
Figure 24: Haematology, South Africa, Company share (%), 2010 66
Figure 25: Histology And Cytology, South Africa, Company share (%), 2010 68
Figure 26: Immuno Chemistry, South Africa, Company share (%), 2010 70
Figure 27: Infectious Immunology, South Africa, Company share (%), 2010 72
Figure 28: Microbiology Culture, South Africa, Company share (%), 2010 74
Figure 29: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, 2003-2017 76
Figure 30: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, Historic, 2003-2010 78
Figure 31: In Vitro Diagnostics, Saudi Arabia, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 80
Figure 32: In Vitro Diagnostics, Saudi Arabia, Company share (%), 2010 86
Figure 33: Clinical Chemistry, Saudi Arabia, Company share (%), 2010 88
Figure 34: Genetic Testing, Saudi Arabia, Company share (%), 2010 90
Figure 35: Haematology, Saudi Arabia, Company share (%), 2010 92
Figure 36: Histology And Cytology, Saudi Arabia, Company share (%), 2010 94
Figure 37: Immuno Chemistry, Saudi Arabia, Company share (%), 2010 96
Figure 38: Infectious Immunology, Saudi Arabia, Company share (%), 2010 98
Figure 39: Microbiology Culture, Saudi Arabia, Company share (%), 2010 100
Figure 40: F. Hoffmann-La Roche Ltd., Company Share (%), Middle East and Africa In Vitro Diagnostics Market, 2010 102
Figure 41: Siemens Healthcare, Company Share (%), Middle East and Africa In Vitro Diagnostics Market, 2010 103
Figure 42: Abbott Laboratories, Company Share (%), Middle East and Africa In Vitro Diagnostics Market, 2010 104
Figure 43: Beckman Coulter, Inc., Company Share (%), iddle East and Africa In Vitro Diagnostics Market, 2010 105
Figure 44: bioMerieux S.A., Company Share (%), Middle East and Africa In Vitro Diagnostics Market, 2010 106
Figure 45: Becton, Dickinson and Company, Company Share (%), Middle East and Africa In Vitro Diagnostics Market, 2010 107

Filed in: In Vitro Diagnostic, Medical Device
Tags: 
More Reports
Title Price Buy Now

In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026

 “The global in vitro fertilization market size is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1 % during the forecast period” The global in vitro fertilization market is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1% from 2021 to 2026. The key factors fueling the growth of this market include an increase in the median age of first-time mothers, declining fertility rates, rising male infertility, rise in obesity rate and growing consumption of alcohol, and growing awareness about the availability of treatment options. However, the high cost and low success rate of IVF treatment and restrictive regulations and ethical concerns are expected to restrict the growth of the IVF market to a certain e......
 $4950

Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within General Surgery therapeutic area. The model discusses in detail the impact of COVID-19 on Assisted Reproductive Technology Devices market for the year 2020 and beyond. Assisted Reproductive Technology (ART) refers to reproductive health procedures that treat infertile women to achieve pregnancy. For decades now across much of the developed world, several techniques of ART have been in use with varying pregnancy success rates. These techniques primarily include, but are no......
 $7500

Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) Summary Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic preg......
 $7500

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 Summary Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing a......
 $10995

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......
 $7500

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......
 $7500

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating ......
 $7500

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......
 $7500

Cytomegalovirus  (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

"Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......
 $7500

Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Prenatal Screening is now routinely used in developed countries for early detection of fetal abnormalities. Various biochemical analytes are measured during the first or second trimester including free-beta human chorionic gonadotropin (hCG), total hCG, pregnancy associated plasma protein-A (PAPP-A), Alpha-fetoprotein (AFP), unconjugated estriol (uE3), and Inhibin A. These markers are used to screen for Down syndrome (Trisomy 21) as well as Edwards syndrome (Trisomy 18) and ectopic pregnancy. Additionally, maternal s......
 $7500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy